Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348374 · ClinicalTrials.gov registry record · Phase 3
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 191
- Enrollment target
NCT00348374 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 191 participants.
The verdict
NCT00348374, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 191 participants
- Enrollment target
Study Summary
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs). Dose titrations will be provided which should allow a large proportion of subjects to reach target glycosylated hemoglobin (A1C) levels.
Interventions
- DRUG Insulin Lispro
- DRUG Exubera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348374
The ClinicalTrials.gov registry entry for NCT00348374 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Lispro is the first listed.
NCT00348374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348374 about?
NCT00348374 is a clinical study titled "Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes". The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs). Dose titrations will be provided which should allow a large proportion of subjects to reach t...
What is the current status of trial NCT00348374?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 191 participants. The study started on 2006-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00348374?
The interventions under investigation include: Insulin Lispro (DRUG), Exubera (DRUG).
Who is sponsoring clinical trial NCT00348374?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.